How does chronic peripheral inflammation interact with CNS neuroimmune pathways to accelerate neurodegeneration? What are the systemic immune signatures that distinguish AD patients from healthy aging, and can peripheral immune biomarkers predict disease progression or treatment response? How does microglial priming by peripheral cytokines alter the brain's response to amyloid and tau pathology?
Anti-CD47/SIRPα Checkpoint Therapy to Enhance Phagocytic Clearance
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["CD47 Expression Amyloid Plaques and Neurons"]
B["SIRPalpha Engagement Microglial Inhibitory Receptor"]
C["SHIP1 and SHP1 Activation Phagocytic Inhibitory Cascade"]
D["Phagocytosis Suppression Reduced Amyloid Clearance"]
E["Amyloid Accumulation Plaque Burden Increase"]
F["Anti-CD47 Antibody Checkpoint Blockade Therapy"]
G["SIRPalpha Disengagement Inhibitory Signal Released"]
H["Microglial Phagocytosis Enhanced Amyloid Clearance"]
A --> B
B --> C
C --> D
D --> E
F -.->|"blocks"| A
F --> G
G -.->|"releases"| D
G --> H
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for CD47/SIRPα axis; target: CD47 on plaques/neurons from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations8 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-18 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses: Systemic Immune Profiling in Neurodegeneration
Hypothesis 1: Circulating hs-CRP as a Disease-Modifying Target via Microglial IL-1β Amplification
Description: Elevated peripheral C-reactive protein (hs-CRP) directly primes hippocampal microglia through IL-1β signaling, creating a feed-forward neuroinflammatory loop that accelerates tau hyperphosphorylation. Therapeutic lowering of hs-CRP may restore microglial surveillance and reduce tau pathology propagation.
Target Gene/Protein: CRP → IL-1β → TLR4/MyD88 axis in microglia
**Supporting Evide
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Systemic Immune Profiling Hypotheses in Neurodegeneration
I will systematically evaluate each hypothesis, identifying specific weaknesses, counter-evidence with PubMed citations, alternative explanations, and key falsification experiments.
Hypothesis 1: Circulating hs-CRP as Disease-Modifying Target via Microglial IL-1β Amplification
Specific Weaknesses in the Evidence
1. Causality vs. Correlation Problem The cited evidence (PMID: 29726919) demonstrates correlation between elevated hs-CRP and cognitive decline but does not establish CRP as a patho
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Expert Evaluation: Systemic Immune Profiling in Neurodegeneration
Executive Summary
The seven hypotheses present a coherent framework linking peripheral immune dysregulation to CNS neurodegeneration, but face significant translational challenges. The fundamental tension is that neuroinflammation-targeting strategies have failed repeatedly in clinical trials (NSAIDs, IL-1 blockade, anti-TNF), suggesting either the wrong targets, wrong timing, or wrong patient populations. I will evaluate each hypothesis against practical criteria.
Hypothesis 1: hs-CRP → Microglial IL-1β
D
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF primary human macrophages or iPSC-derived microglia are treated with blocking anti-CD47 antibody (or SIRPα-Fc fusion protein) ex vivo, THEN phagocytic uptake of fluorescently-labeled neuritic plaque material (synthetic Aβ42 aggregates) will increase by >50% within 48 hours compared to IgG isotype control treatment.
pendingconf: 0.45
Expected outcome: Phagocytic index increases from baseline (~0.3) to >0.45 (50% increase) when treated with anti-CD47/SIRPα blockade
Falsified by: Phagocytic index remains unchanged (<10% increase) or decreases with anti-CD47 treatment compared to vehicle/isotype control
Method: In vitro phagocytosis assay using primary human monocyte-derived macrophages or iPSC-derived microglia with pHrodo-labeled synthetic Aβ42 fibrils, quantified by flow cytometry or fluorescence microscopy
IF 5xFAD transgenic mice (Alzheimer's disease model) receive intravenous administration of anti-CD47 antibody (0.5 mg/kg, biweekly for 4 weeks), THEN cortical and hippocampal amyloid plaque burden will decrease by >30% compared to vehicle-treated 5xFAD mice, as measured by in vivo [11C]PiB PET or post-mortem Thioflavin-S histology.
pendingconf: 0.35
Expected outcome: Amyloid plaque burden decreases by >30% in anti-CD47 treated mice (from ~15% plaque area to <10.5%)
Falsified by: No significant reduction in amyloid plaque burden (<15% decrease) or plaque load increases with anti-CD47 treatment
Method: Randomized controlled study in 6-month-old 5xFAD mice (n=15/group), anti-mouse CD47 antibody (MIAP301 or clone B6H12) vs. IgG control, 4-week treatment duration, outcome measured by in vivo PET or blinded histological quantification